Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Marex Group plc due to allegations of securities law violations, encouraging affected investors to contact them directly [1][3][4]. Group 1: Allegations Against Marex - The complaint alleges that Marex and its executives made false or misleading statements and failed to disclose critical information, including the sale of over-the-counter financial instruments to itself and inconsistencies in financial statements [3]. - A report from NINGI Research accused Marex of a multi-year accounting scheme involving off-balance-sheet entities and fictitious transactions to hide losses and inflate profits, citing a fabricated receivable of $17 million and nearly $1 billion in concealed derivatives exposure [4]. - Following the release of the report, Marex's stock experienced a significant decline of 6.2%, closing at $35.31 on heavy trading volume [5]. Group 2: Legal Proceedings and Investor Actions - The deadline for investors to seek the role of lead plaintiff in the federal securities class action against Marex is December 8, 2025, with the lead plaintiff being the investor with the largest financial interest [1][6]. - Faruqi & Faruqi encourages anyone with information regarding Marex's conduct, including whistleblowers and former employees, to come forward [6].
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Marex Group